1. Report Industry Investment Rating No relevant content provided. 2. Core Viewpoints of the Report The report presents the top ten convertible bonds for December 2025, analyzing each bond's issuer, including its financial performance, business scope, and key attractions [1][3][4]. 3. Summary by Company 3.1 Zhongte Convertible Bond - **Company Profile**: A globally leading specialized special steel material manufacturing enterprise with a production capacity of about 20 million tons of special steel materials per year [11]. - **Financial Performance**: In 2024, its operating income was 109.203 billion yuan (YoY -4.22%), and the net profit attributable to the parent was 5.126 billion yuan (YoY -10.41%). In the first three quarters of 2025, the operating income was 81.206 billion yuan (YoY -2.75%), and the net profit attributable to the parent was 4.33 billion yuan (YoY +12.88%) [11]. - **Company Highlights**: It is one of the world's most comprehensive special steel enterprises in terms of variety and specifications, with leading market shares in core products such as bearing steel and automotive steel. It has a complete industrial chain and strong cost - control capabilities, and is actively seeking external expansion [12]. 3.2 Shanlu Convertible Bond - **Company Profile**: Mainly engaged in road and bridge engineering construction and maintenance, and actively expanding into other fields. It has a complete business and management system [29]. - **Financial Performance**: In 2024, its operating income was 71.348 billion yuan (YoY -2.3%), and the net profit attributable to the parent was 2.322 billion yuan (YoY +1.47%). In the first three quarters of 2025, the operating income was 41.354 billion yuan (YoY -3.11%), and the net profit attributable to the parent was 1.41 billion yuan (YoY -3.27%) [29]. - **Company Highlights**: Controlled by the Shandong Provincial State - owned Assets Supervision and Administration Commission, it has the concept of "China Special Valuation". It is expected to benefit from infrastructure construction in Shandong and the "Belt and Road" initiative [30]. 3.3 Hebang Convertible Bond - **Company Profile**: With advantages in salt mines, phosphate mines, and natural gas supply, it has completed the basic layout in the chemical, agricultural, and photovoltaic fields [44]. - **Financial Performance**: In 2024, its operating income was 8.547 billion yuan (YoY -3.13%), and the net profit attributable to the parent was 31 million yuan (YoY -97.55%). In the first three quarters of 2025, the operating income was 5.927 billion yuan (YoY -13.02%), and the net profit attributable to the parent was 93 million yuan (YoY -57.93%) [44]. - **Company Highlights**: Its phosphate mines and salt mines contribute stable profits, and the liquid methionine business has high - margin performance [45]. 3.4 Huayuan Convertible Bond - **Company Profile**: Focused on building a complete vitamin D3 upstream - downstream industrial chain, with products including cholesterol, vitamin D3, and chemical preparations [57]. - **Financial Performance**: In 2024, its operating income was 1.243 billion yuan (YoY +13.58%), and the net profit attributable to the parent was 309 million yuan (YoY +60.76%). In the first three quarters of 2025, the operating income was 936 million yuan (YoY -0.2%), and the net profit attributable to the parent was 234 million yuan (YoY -3.07%) [57]. - **Company Highlights**: It is a leader in NF - grade cholesterol and 25 - hydroxyvitamin D3 products. It is expanding its product matrix and has a layout in the pharmaceutical manufacturing field [58]. 3.5 Xingye Convertible Bond - **Company Profile**: One of the first joint - stock commercial banks approved by the State Council and the People's Bank of China, evolving into a modern financial service group [71]. - **Financial Performance**: In 2024, its operating income was 212.226 billion yuan (YoY +0.66%), and the net profit attributable to the parent was 77.205 billion yuan (YoY +0.12%). In the first three quarters of 2025, the operating income was 161.234 billion yuan (YoY -1.82%), and the net profit attributable to the parent was 63.083 billion yuan (YoY +0.12%) [71]. - **Company Highlights**: It has stable asset quality and scale growth, with a large number of corporate and retail customers [72]. 3.6 Huanxu Convertible Bond - **Company Profile**: A global leader in electronic manufacturing design, providing value - added services to brand customers [81]. - **Financial Performance**: In 2024, its operating income was 60.691 billion yuan (YoY -0.17%), and the net profit attributable to the parent was 1.652 billion yuan (YoY -15.16%). In the first three quarters of 2025, the operating income was 43.641 billion yuan (YoY -0.83%), and the net profit attributable to the parent was 1.263 billion yuan (YoY -2.6%) [81]. - **Company Highlights**: It is a leading manufacturer of smart wearable SiP modules, with advanced packaging technologies and a global production layout [82]. 3.7 Chongyin Convertible Bond - **Company Profile**: The earliest local joint - stock commercial bank in the upper reaches of the Yangtze River and Southwest China, listed on the Hong Kong Stock Exchange and selected for the "Leading Bank" program [94]. - **Financial Performance**: In 2024, its operating income was 13.679 billion yuan (YoY +3.54%), and the net profit attributable to the parent was 5.117 billion yuan (YoY +3.8%). In the first three quarters of 2025, the operating income was 11.74 billion yuan (YoY +10.4%), and the net profit attributable to the parent was 4.879 billion yuan (YoY +10.19%) [94]. - **Company Highlights**: Benefiting from the Chengdu - Chongqing economic circle strategy, it has stable asset - scale growth and a reasonable credit strategy [96]. 3.8 Tianye Convertible Bond - **Company Profile**: The first industrial enterprise of the Xinjiang Production and Construction Corps and a leading enterprise in the chlor - alkali chemical industry, with an integrated circular economy industrial chain [103]. - **Financial Performance**: In 2024, its operating income was 11.156 billion yuan (YoY -2.7%), and the net profit attributable to the parent was 68 million yuan (YoY +108.83%). In the first three quarters of 2025, the operating income was 7.97 billion yuan (YoY +2.2%), and the net profit attributable to the parent was 7 million yuan (YoY -28.79%) [103]. - **Company Highlights**: The cost of caustic soda production is relatively fixed, and it plans to increase the dividend frequency and has coal - mine projects in progress [106]. 3.9 Aorui Convertible Bond - **Company Profile**: A company focusing on the R & D, production, and sales of complex APIs and preparations, leading in several technical fields [119]. - **Financial Performance**: In 2024, its operating income was 1.476 billion yuan (YoY +16.89%), and the net profit attributable to the parent was 355 million yuan (YoY +22.59%). In the first three quarters of 2025, the operating income was 1.237 billion yuan (YoY +13.67%), and the net profit attributable to the parent was 354 million yuan (YoY +24.58%) [119]. - **Company Highlights**: It has an optimized distributor network, expanding preparation products, and high - quality customer resources [120]. 3.10 Yushui Convertible Bond - **Company Profile**: The largest water supply and drainage integrated enterprise in Chongqing, with a stable monopoly position in the local market [133]. - **Financial Performance**: In 2024, its operating income was 6.999 billion yuan (YoY -3.52%), and the net profit attributable to the parent was 785 million yuan (YoY -27.88%). In the first three quarters of 2025, the operating income was 5.568 billion yuan (YoY +7.21%), and the net profit attributable to the parent was 779 million yuan (YoY +7.1%) [133]. - **Company Highlights**: It has a high market share in Chongqing, is expanding externally, and has effective cost - control measures [134].

Group 1 - The company Garden Bio announced on November 24 that as of November 20, 2025, the total number of shareholders is 28,552 [2]

Core Insights - Garden Biologics experienced a decline of 2.73% in stock price on November 20, with a trading volume of 164 million yuan [1] - The company reported a financing buy-in amount of 24.2 million yuan and a net financing buy of 1.3 million yuan on the same day [1][2] - As of November 20, the total financing and securities lending balance for Garden Biologics was 548 million yuan, with a financing balance of 547 million yuan, representing 7.26% of the circulating market value [1] Financing and Securities Lending - On November 20, the financing buy-in for Garden Biologics was 24.2 million yuan, with a financing balance of 547 million yuan, which is below the 10% percentile level over the past year [1] - The company repaid 6,900 shares in securities lending and sold 29,300 shares, with a selling amount of 406,400 yuan [1] - The securities lending balance was 773,900 yuan, which is above the 60% percentile level over the past year, indicating a relatively high position [1] Company Overview - Garden Biologics, established on December 18, 2000, and listed on October 9, 2014, is located in Jinhua City, Zhejiang Province [1] - The company's main business focuses on developing, producing, and selling products related to a complete vitamin D3 industry chain [1] - The revenue composition includes vitamin products (47.41%), pharmaceuticals (30.22%), lanolin and derivatives (20.93%), and other minor segments [1] Financial Performance - For the period from January to September 2025, Garden Biologics reported a revenue of 936 million yuan, a slight decrease of 0.20% year-on-year [2] - The net profit attributable to the parent company was 234 million yuan, reflecting a year-on-year decrease of 3.07% [2] Shareholder Information - As of November 10, the number of shareholders for Garden Biologics was 29,100, an increase of 2.11% from the previous period [2] - The average circulating shares per person decreased by 2.06% to 18,378 shares [2] - Cumulatively, the company has distributed 446 million yuan in dividends since its A-share listing, with 178 million yuan distributed over the past three years [3]

Core Viewpoint - Garden Biologics' stock has shown fluctuations with a recent increase of 2.14%, reflecting a total market capitalization of 7.788 billion yuan, while the company continues to focus on developing a complete vitamin D3 industry chain [1] Financial Performance - For the period from January to September 2025, Garden Biologics reported a revenue of 936 million yuan, a slight decrease of 0.20% year-on-year, and a net profit attributable to shareholders of 234 million yuan, down 3.07% year-on-year [2] - Cumulative cash dividends since the company's A-share listing amount to 446 million yuan, with 178 million yuan distributed over the past three years [3] Shareholder Information - As of November 10, 2025, the number of shareholders for Garden Biologics reached 29,100, an increase of 2.11% from the previous period, while the average circulating shares per person decreased by 2.06% to 18,378 shares [2] - The top ten circulating shareholders include Southern CSI 1000 ETF, holding 3.4785 million shares, which decreased by 48,400 shares compared to the previous period [3] Stock Performance - Year-to-date, Garden Biologics' stock price has decreased by 1.48%, but it has seen a 1.70% increase over the last five trading days and a 6.62% increase over the last twenty days [1]

Group 1 - The core point of the article is that Huayuan Biological (300401) reported a total of 29,090 shareholders as of November 10, 2025 [1]

Core Viewpoint - Garden Biologics announced that its subsidiary, Huayuan Pharmaceutical, has won the bid for Alendronate Sodium Tablets in the 11th batch of national centralized drug procurement organized by the National Drug Procurement Office on November 7 [1] Group 1 - The announcement was made on November 7, coinciding with the release of the procurement results [1] - Alendronate Sodium Tablets are now part of the national centralized procurement, which may impact the company's market position and sales [1]

Core Viewpoint - Garden Biologics' subsidiary, Zhejiang Garden Pharmaceutical Co., Ltd., has been selected in the 11th batch of national centralized drug procurement, which is expected to enhance market penetration and brand influence for the company's Alendronate Sodium Tablets [1] Group 1 - The national centralized procurement results were announced on November 7, indicating that Garden Pharmaceutical's Alendronate Sodium Tablets have been selected [1] - The selection is anticipated to facilitate rapid market expansion and increase market share for the product [1] - This development is expected to promote the growth of the company's pharmaceutical formulation business and enrich its product pipeline [1]

Core Viewpoint - Garden Biologics (300401.SZ) announced that its subsidiary, Zhejiang Garden Pharmaceutical Co., Ltd., has been selected in the 11th batch of national centralized drug procurement, which will enhance the market penetration of its Alendronate Sodium Tablets and promote the development of its pharmaceutical formulation business [1] Group 1 - The selection of Alendronate Sodium Tablets in the national procurement will facilitate rapid market expansion for the product [1] - This development is expected to increase the market share of the product, thereby enriching the company's product pipeline [1] - The outcome will also enhance the brand influence of the company in the pharmaceutical industry [1]

Group 1 - The core point of the article is that Huayuan Biopharmaceutical (300401.SZ) announced that its wholly-owned subsidiary, Zhejiang Huayuan Pharmaceutical Co., Ltd., has been selected for the national centralized procurement of its product, Alendronate Sodium Tablets [1] Group 2 - The product is indicated primarily for the treatment of osteoporosis in postmenopausal women and for increasing bone mass in men with osteoporosis [1]

Group 1 - Garden Biologics announced that its subsidiary, Zhejiang Garden Pharmaceutical Co., Ltd., won the bid for Alendronate Sodium Tablets in the 11th batch of national centralized drug procurement [1] - For the year 2024, the revenue composition of Garden Biologics is projected to be 65.08% from vitamins and 34.92% from the pharmaceutical manufacturing sector [1] - As of the report, the market capitalization of Garden Biologics is 7.5 billion yuan [1]